E3 PreliminaryPreliminaryPEM unclearCase-ControlPeer-reviewedMachine draft
Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists--preliminary results.
Späth, M, Welzel, D, Färber, L · Scandinavian journal of rheumatology. Supplement · 2000
Quick Summary
Researchers tested whether two medications that block serotonin receptors (tropisetron and ondansetron) might help ME/CFS patients feel less fatigued. About one third of the patients who took these medications reported meaningful improvement in fatigue and energy levels over 15 days, with no serious side effects reported.
Why It Matters
This is one of the earliest investigations of 5-HT3 antagonists in ME/CFS, based on emerging evidence of serotonergic dysfunction. Even this preliminary finding of one third response rates provided rationale for more rigorous controlled trials, and contributed to understanding potential neuroimmunological mechanisms in ME/CFS.
Observed Findings
- In the tropisetron group (n=9 completers): 6/9 (67%) showed fatigue improvement and 7/9 (78%) showed capability improvement on VAS
- In the ondansetron group (n=10): 8/10 (80%) showed fatigue improvement and 8/10 (80%) showed capability improvement on VAS
- Approximately one third of combined cohort achieved ≥35% improvement on both VAS measures
- Score changes were larger in tropisetron responders compared to ondansetron responders
- Treatment was well-tolerated with no serious adverse effects reported
Inferred Conclusions
- 5-HT3 receptor antagonists may have therapeutic potential in a subset of ME/CFS patients
- Both tropisetron and ondansetron showed similar response rates, suggesting a drug class effect
- The findings warrant placebo-controlled, double-blind trials to confirm efficacy beyond placebo response
Remaining Questions
- What proportion of improvement is due to placebo effect versus specific drug action?
- How long do improvements persist beyond the 15-day treatment period?
- Which patient characteristics predict who will respond to 5-HT3 antagonists?
What This Study Does Not Prove
This small, uncontrolled open-label study does not prove efficacy—response could reflect placebo effect, natural disease fluctuation, or observer bias. The 15-day treatment window is too short to assess durability of benefit or long-term safety. Results cannot be generalized beyond the small sample studied.
Tags
Symptom:Fatigue
Method Flag:PEM Not DefinedNo ControlsSmall SampleExploratory Only
Metadata
- PMID
- 11028837
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →